Results 61 to 70 of about 718,683 (284)

A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy

Journal of Ovarian Research
Background The efficacy of subsequent therapy after poly-ADP-ribose polymerase (PARP) inhibitor maintenance treatment has raised concerns. Retrospective studies show worse outcomes for platinum-based chemotherapy after progression of PARP inhibitor ...
Nan Zhang, Hong Zheng, Yunong Gao, Tong Shu, Hongguo Wang, Yan Cai   +5 more
doaj   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice.

, 2005
Poly(ADP-ribose) polymerase-1 (PARP) inhibitors have been investigated as enhancers of chemotherapy. We recently showed that PARP inhibitor GPI 15427 increases the anti-tumor efficacy of temozolomide (TMZ) in mice. To select a PARP inhibitor for clinical
C. Leonetti, M. Vergati, Tentori, L, J. Zhang, G. Graziani, GRAZIANI, GRAZIA, Vergati, M, TENTORI, LUCIO, M. Scarsella, Graziani, G, A. Muzi, Leonetti, C, and and the Guilford PARP Project Group, Scarsella, M, Muzi, A, Lapidus, RG, MUZI, ALESSIA, L. Tentori, R. G. Lapidus, and the Guilford PARP Project Group, Zhang, J   +20 more
core   +2 more sources

p21CDKN1A Regulates the Binding of Poly(ADP-Ribose) Polymerase-1 to DNA Repair Intermediates. [PDF]

PLoS ONE, 2016
The cell cycle inhibitor p21CDKN1A was previously found to interact directly with DNA nick-sensor poly(ADP-ribose) polymerase-1 (PARP-1) and to promote base excision repair (BER).
Ilaria Dutto, Maria Sukhanova, Micol Tillhon, Ornella Cazzalini, Lucia A Stivala, A Ivana Scovassi, Olga Lavrik, Ennio Prosperi   +7 more
doaj   +1 more source

PARP inhibitors in ovarian cancer [PDF]

Annals of Oncology, 2016
Slow progress in improving the outcome of ovarian cancer with chemotherapy over the last decade has stimulated research into molecularly targeted therapy. Poly(ADP-ribose) polymerase (PARP) inhibitors target DNA repair and are specifically active in cells that have impaired repair of DNA by the homologous recombination (HR) pathway.
openaire   +3 more sources

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

Mitotic Spindle +/- PARP inhibitor Olaparib

, 2022
Epimastigotes synchronized (images correpond to the G2-M phase of the cycle) incubated in the presence of DMSO control (Figures 1-28) or in the presence of 100 nM Olaparib  PARP inhibitor (Figures 27-41). Spindle is visualized with antitubulin antibody. 
Laura Kevorkian (13577728)
core   +1 more source

Regulation of the lncRNA NEAT1 by p53‐ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC

Molecular Oncology, EarlyView.
In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico, Veronica La Banca, Silvia D'Amico, Stefano Scalera, Sara Nicolai, Angelo Peschiaroli   +5 more
wiley   +1 more source

PARP Inhibitors in Ovarian Cancer [PDF]

Recent Patents on Anti-Cancer Drug Discovery, 2018
Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical ...
Gloria, Mittica, Eleonora, Ghisoni, Gaia, Giannone, Sofia, Genta, Massimo, Aglietta, Anna, Sapino, Giorgio, Valabrega   +6 more
openaire   +2 more sources